uniQure Announces Presentations at Upcoming April
Post# of 301275
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE ), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced presentations at the following conferences taking place in April:
World Orphan Drug Congress USA, April 19 – 21 2017, at the Washington Marriott Wardman Park in Washington D.C.
- Matt Kapusta, Chief Executive Officer, will be presenting a keynote address: Adeno-associated virus (AAV)-based gene therapies for rare, chronic and degenerative diseases, on Friday April 21 st , 2017, 9.40 a.m. EDT.
12th Annual HD Therapeutics Conference by CHDI, April 24 – 27 2017, at the Westin Dragonara Resort in St. Julian’s, Malta.
- A presentation new preclinical data on huntingtin gene silencing in a mini-pig model of Huntington’s Disease, using allele-specific and non-selective miRNAs, will be presented during the CHDI conference.
Gene Therapy for Rare Disorders Conference, April 25 – 26 2017, at the Sheraton Boston Hotel, in Boston MA.
- Lance Weed, Vice President of US Operations, will be presenting: Optimizing the Scalability of Gene Therapy Manufacturing, on Tuesday April 25 th , 2017, 2.00 p.m. EDT.
- Eileen Sawyer, Director of Global Medical Affairs, will be presenting: Bridging Gaps Through Early Integration of the Internal Medical Affairs Function, on Wednesday April 26 th , 2017, 11.00 a.m. EDT.
- Daniel Leonard, Director of Global Patient Advocacy, will be presenting: The Intersection of Patient Advocacy and Gene Therapy: A Case Study in Hemophilia, on Wednesday April 26 th , 2017, 2.00 p.m. EDT.
Alliance for Regenerative Medicines (ARM)’s 5 th Annual Cell & Gene Therapy Investor Day, April 27 th 2017, at The State Room, in Boston MA.
- Matthew Kapusta, chief executive officer, will be participating in a fireside chat on Thursday, April 27 th , 2017, 2.15 p.m. EDT.
The Company also announced its participation in the following conferences taking place in April:
Hemophilia Federation of America (HFA)’s Annual Symposium, April 6 – 9 2017, at the Rhode Island Convention Center in Providence, RI.
The International Liver Congress 2017 by EASL, April 19 – 23 2017 at the RAI in Amsterdam, The Netherlands.
About uniQure uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 m.cantor@uniQure.com Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 e.mulder@uniQure.com Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 t.malone@uniQure.com
(0)
(0)